166 related articles for article (PubMed ID: 35583393)
21. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
23. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
24. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.
Sánchez-Martínez C; Gelbert LM; Lallena MJ; de Dios A
Bioorg Med Chem Lett; 2015 Sep; 25(17):3420-35. PubMed ID: 26115571
[TBL] [Abstract][Full Text] [Related]
25. Cell cycle-mediated regulation of hepatic regeneration.
Ehrenfried JA; Ko TC; Thompson EA; Evers BM
Surgery; 1997 Nov; 122(5):927-35. PubMed ID: 9369893
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase inhibitors closer to market launch?
Galons H; Oumata N; Gloulou O; Meijer L
Expert Opin Ther Pat; 2013 Aug; 23(8):945-63. PubMed ID: 23600454
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019).
Wang PF; Qiu HY; He Y; Zhu HL
Expert Opin Ther Pat; 2020 Oct; 30(10):795-805. PubMed ID: 32945222
[TBL] [Abstract][Full Text] [Related]
28. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
30. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
32. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
33. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
34. Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S
Drug Discov Today; 2020 Feb; 25(2):406-413. PubMed ID: 31839441
[TBL] [Abstract][Full Text] [Related]
35. CDK2 regulation through PI3K and CDK4 is necessary for cell cycle progression of primary rat hepatocytes.
Wierød L; Rosseland CM; Lindeman B; Oksvold MP; Grøsvik H; Skarpen E; Huitfeldt HS
Cell Prolif; 2007 Aug; 40(4):475-87. PubMed ID: 17635516
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Law ME; Corsino PE; Narayan S; Law BK
Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Basso AD; Doll RJ
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
[TBL] [Abstract][Full Text] [Related]
40. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
Duca JS
Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
